Hemolytic anemia screening: Difference between revisions
m (Template) |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hemolytic anemia}} | {{Hemolytic anemia}} | ||
{{CMG}} | {{CMG}} {{shyam}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
| Line 8: | Line 8: | ||
==Screening== | ==Screening== | ||
In some cases, screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency can be done to determine if a patient is at risk for hemolytic anemia. Primaquine, sulfa drugs, and fava beans can trigger hemolytic crises in the setting of G6PD deficiency.<ref name="pmid24372186">{{cite journal| author=Luzzatto L, Seneca E| title=G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. | journal=Br J Haematol | year= 2014 | volume= 164 | issue= 4 | pages= 469-80 | pmid=24372186 | doi=10.1111/bjh.12665 | pmc=4153881 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24372186 }} </ref> Rasburicase has also been shown to trigger hemolytic episodes, so G6PD screening is important prior to administration of rasburicase.<ref name="pmid24372186">{{cite journal| author=Luzzatto L, Seneca E| title=G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. | journal=Br J Haematol | year= 2014 | volume= 164 | issue= 4 | pages= 469-80 | pmid=24372186 | doi=10.1111/bjh.12665 | pmc=4153881 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24372186 }} </ref> | |||
==References== | ==References== | ||
Revision as of 19:11, 31 August 2017
|
Hemolytic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hemolytic anemia screening On the Web |
|
American Roentgen Ray Society Images of Hemolytic anemia screening |
|
Risk calculators and risk factors for Hemolytic anemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Screening
In some cases, screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency can be done to determine if a patient is at risk for hemolytic anemia. Primaquine, sulfa drugs, and fava beans can trigger hemolytic crises in the setting of G6PD deficiency.[1] Rasburicase has also been shown to trigger hemolytic episodes, so G6PD screening is important prior to administration of rasburicase.[1]
References
- ↑ 1.0 1.1 Luzzatto L, Seneca E (2014). "G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications". Br J Haematol. 164 (4): 469–80. doi:10.1111/bjh.12665. PMC 4153881. PMID 24372186.